Key Findings:
- With some exceptions, HER2-Low (H2L) breast cancer shares genomic features with its more classically defined subset of either HR+ or HR- disease.
- Notable differences in PIK3CA (an actionable mutation) and TP53 (a prognostic alteration) warrant additional assessment, as do amplifications variable between HR+H2L and HR+HER2-positive groups.